{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasm+Recurrent&page=79", "query": { "condition": "Neoplasm Recurrent", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 8510, "total_pages": 851, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasm+Recurrent&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasm+Recurrent&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T18:07:00.243Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06948786", "title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2025-11-17", "completion_date": "2031-07-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948786" }, { "nct_id": "NCT00100854", "title": "Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2004-10-28", "completion_date": "2018-09-05", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100854" }, { "nct_id": "NCT03218683", "title": "Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "AZD5991", "type": "DRUG" }, { "name": "AZD5991 + Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 70, "start_date": "2017-08-02", "completion_date": "2021-10-08", "has_results": false, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 10, "location_summary": "Orange, California • Aurora, Colorado • Atlanta, Georgia + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03218683" }, { "nct_id": "NCT04424966", "title": "Infigratinib in Recurrent High-Grade Glioma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioma", "Glioblastoma", "GBM" ], "interventions": [ { "name": "Infigratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nader Sanai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-07-21", "completion_date": "2024-02-19", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 3, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04424966" }, { "nct_id": "NCT00408551", "title": "Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "floxuridine", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Goshen Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2005-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 1, "location_summary": "Goshen, Indiana", "locations": [ { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408551" }, { "nct_id": "NCT00176631", "title": "Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "licorice root extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 10, "start_date": "2007-09", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2023-12-22", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176631" }, { "nct_id": "NCT00923117", "title": "Sunitinib to Treat Recurrent Brain Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Malignant Gliomas", "Anaplastic Gliomas" ], "interventions": [ { "name": "Sutent (sunitinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2008-06", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923117" }, { "nct_id": "NCT00450450", "title": "Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Juvenile Myelomonocytic Leukemia", "Previously Treated Myelodysplastic Syndromes", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 27, "start_date": "2007-12-31", "completion_date": "2022-03-31", "has_results": true, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 21, "location_summary": "Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450450" }, { "nct_id": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1303/BNT323", "type": "BIOLOGICAL" }, { "name": "Pertuzumab Injection", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 796, "start_date": "2022-01-31", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 35, "location_summary": "Cerritos, California • Los Angeles, California • San Diego, California + 29 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05150691" }, { "nct_id": "NCT06771674", "title": "Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hookipa Biotech GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 662, "start_date": "2024-06-05", "completion_date": "2025-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-11-13T18:07:00.243Z", "location_count": 1, "location_summary": "Dublin, Ohio", "locations": [ { "city": "Dublin", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06771674" } ] }